13h
Zacks Investment Research on MSNHow to Play VKTX Stock Amid Manufacturing Deal With CordenPharmaShares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
5h
Zacks Investment Research on MSNViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteViking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.
1don MSN
Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...
Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...
1d
Zacks.com on MSNVKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyThe deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...
Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...
After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...
Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock. VKTX’s Progress With Its Obesity Program Encouraging VK2735 has shown ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results